Nathan Ford, Roz Scourse, Maud Lemoine, Yvan Hutin, Marc Bulterys, Zara Shubber, Dmytro Donchuk, Gilles Wandeler – 25 September 2018 – Successful treatment outcomes for chronic hepatitis B virus (HBV) infection requires high levels of adherence to treatment. We searched three databases and abstracts from two conferences up to January 2018 for studies reporting the proportion of patients who were adherent to HBV antiviral therapy and pooled data using random effects meta‐analysis. We included 30 studies, providing data for 23,823 patients.

Hannes Hagström, Jonas Höijer, Hanns‐Ulrich Marschall, Catherine Williamson, Michael A. Heneghan, Rachel H. Westbrook, Jonas F. Ludvigsson, Olof Stephansson – 25 September 2018 – There are limited data on pregnancy outcomes in women with cirrhosis. To address this gap, we examined the records of singleton births from Sweden’s National Patient Register (NPR), Cause of Death Register (CDR), and Medical Birth Register (MBR) between 1997 and 2011 to assess exposure and pregnancy‐related and liver‐related outcomes of pregnant women with cirrhosis.

Kenneth Leung, Michael Quezada, Zhengshan Chen, Gary Kanel, Neil Kaplowitz – 25 September 2018 – Niacin (vitamin B3) is available as a prescription medication and over‐the‐counter supplement. Although it is well known for its vasodilatory effect, it has also been associated with mild hepatotoxicity and, rarely, acute liver failure. We present the case of a 74‐year‐old Hispanic woman who developed acute liver failure (anicteric encephalopathy and coagulopathy) after her home dose of immediate‐release niacin was replaced with an extended‐release formulation during an inpatient hospital stay.

Mark R. Deneau, Cara Mack, Reham Abdou, Mansi Amin, Achiya Amir, Marcus Auth, Fateh Bazerbachi, Anne Marie Broderick, Albert Chan, Matthew DiGuglielmo, Wael El‐Matary, Mounif El‐Youssef, Federica Ferrari, Katryn N. Furuya, Frederic Gottrand, Nitika Gupta, Matjaž Homan, M.K. Jensen, Binita M. Kamath, Kyung Mo Kim, Kaija‐Leena Kolho, Anastasia Konidari, Bart Koot, Raffaele Iorio, Mercedes Martinez, Parvathi Mohan, Sirish Palle, Alexandra Papadopoulou, Amanda Ricciuto, Lawrence Saubermann, Pushpa Sathya, Eyal Shteyer, Vratislav Smolka, Atsushi Tanaka, Pamela L.

Alphonse E. Sirica, Gregory J. Gores, John D. Groopman, Florin M. Selaru, Mario Strazzabosco, Xin Wei Wang, Andrew X. Zhu – 25 September 2018 – Intrahepatic cholangiocarcinoma (iCCA) has over the last 10‐20 years become the focus of increasing concern, largely due to its rising incidence and high mortality rates worldwide.

Christoph Boesecke, Jürgen K. Rockstroh – 25 September 2018

24 September 2018

YanChao Jiang, Yi Huang, ShiYing Cai, YongFeng Song, James L. Boyer, KeZhong Zhang, Ling Gao, JiaJun Zhao, WenDong Huang, Guang Liang, Suthat Liangpunsakul, Li Wang – 24 September 2018 – Long noncoding RNA (lncRNA) H19 is abundantly expressed in fetal liver. Its expression is significantly diminished in adult healthy liver but is re‐induced in chronic liver diseases, including cholestasis.

Jie Wang, Xiangmei Chen, Yali Wu, Zhenhuan Cao, Leijie Wang, Hongxin Huang, Xinyue Chen, Fengmin Lu – 24 September 2018

Patrick R. Brown, Omar Sadiq, Alexander Weick, Adrienne Lenhart, Mohammad Elbatta, Christopher Fernandez, Anas Kutait, Robert Pompa, Syed‐Mohammed Jafri – 24 September 2018 – Ledipasvir‐sofosbuvir, a once‐a‐day, oral combination pill, was approved in 2014 for the treatment of chronic hepatitis C infection. Initial trials did not comment on nephrotoxicity; however, recent data suggest a risk of acute kidney injury (AKI) with the use of the medication. We assessed the rates of AKI in patients undergoing ledipasvir‐sofosbuvir in a large, urban tertiary care center.